These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27641478)

  • 1. Mutational subgroups for oesophageal adenocarcinoma.
    Burki TK
    Lancet Oncol; 2016 Oct; 17(10):e426. PubMed ID: 27641478
    [No Abstract]   [Full Text] [Related]  

  • 2. Definitions of oesophageal cancer.
    Burki TK
    Lancet Oncol; 2017 Feb; 18(2):e71. PubMed ID: 28089633
    [No Abstract]   [Full Text] [Related]  

  • 3. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors.
    Kunzmann AT; Cañadas Garre M; Thrift AP; McMenamin ÚC; Johnston BT; Cardwell CR; Anderson LA; Spence AD; Lagergren J; Xie SH; Smyth LJ; McKnight AJ; Coleman HG
    Gastroenterology; 2019 Jan; 156(1):43-45. PubMed ID: 30243622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.
    Salati M; Venetis K; Fassan M; Malapelle U; Pagni F; Sajjadi E; Fusco N; Ghidini M
    Future Oncol; 2021 Nov; 17(33):4607-4618. PubMed ID: 34406032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
    Pishvaian MJ; Brody JR
    Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multigene Panel Testing in Oncology Practice: How Should We Respond?
    Kurian AW; Ford JM
    JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167
    [No Abstract]   [Full Text] [Related]  

  • 9. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
    Horlings HM; Shah SP; Huntsman DG
    JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
    [No Abstract]   [Full Text] [Related]  

  • 10. Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool?
    Nason KS
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2286-7. PubMed ID: 25444198
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib-sensitizing mutations in esophageal carcinoma.
    Guo M; Liu S; Lu F
    N Engl J Med; 2006 May; 354(20):2193-4. PubMed ID: 16707764
    [No Abstract]   [Full Text] [Related]  

  • 13. Personalized targeted therapy for esophageal squamous cell carcinoma.
    Kang X; Chen K; Li Y; Li J; D'Amico TA; Chen X
    World J Gastroenterol; 2015 Jul; 21(25):7648-58. PubMed ID: 26167067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of Genomic Sequencing in Pediatric CNS Tumors.
    Bavle AA; Lin FY; Parsons DW
    Oncology (Williston Park); 2016 May; 30(5):411-23. PubMed ID: 27188671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?
    Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A
    Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459
    [No Abstract]   [Full Text] [Related]  

  • 16. Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse.
    Stearns V; Park BH
    JAMA Oncol; 2015 Aug; 1(5):569-70. PubMed ID: 26182336
    [No Abstract]   [Full Text] [Related]  

  • 17. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
    Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
    Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Single Gene Mutation in Esophageal Adenocarcinoma.
    Lee KTW; Smith RA; Gopalan V; Lam AK
    Methods Mol Biol; 2018; 1756():213-229. PubMed ID: 29600373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 20. Personalising the treatment of prostate cancer.
    Gunjur A
    Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.